Acum 17 h
Global Payments, Insulet, and SolarEdge Post Q4 2025 Results and Issue 2026 Guidance
Global Payments, Insulet, and SolarEdge released their fourth-quarter 2025 figures, highlighting differing trends in revenue, earnings, and profitability. Global Payments and Insulet both topped revenue expectations, while SolarEdge reported a GAAP net loss despite strong year-over-year sales growth. All three companies set targets for 2026, outlining guidance on revenue expansion, margins, and earnings growth.
Acum 17 h
Acum 18 h
Western Digital to Unload $3.17B Sandisk Stake at Discount, SNDK Slides Ahead of February 18, 2026 Session
Sandisk Corporation's stock declined on February 18, 2026, after Western Digital moved to sell $3.17 billion worth of its shares in a discounted secondary offering. The deal, involving a debt-for-equity swap with J.P. Morgan and BofA Securities, comes at up to a 9.4% discount to the prior close and put further pressure on SNDK in premarket trading. Despite the short-term drop, Sandisk has delivered triple-digit returns over the past year amid a NAND flash shortage and strong earnings.
Acum 18 h
2-13
Palantir Shares Drop Over 6% After Michael Burry's 10,000-Word Critique of AI Investment Boom
Palantir Technologies shares fell as much as 6.7% on February 12 and continued lower in premarket trading on February 13 after Michael Burry released a 10,000-word newsletter criticizing the durability of the current AI investment cycle and warning the stock could decline sharply. While Burry outlined potential downside of up to 66%, other analysts highlighted Palantir's rapid growth, strong cash position and premium valuation, underscoring the divide over how sustainable its AI-driven momentum really is.
2-13
2-11
Moderna Shares Sink 9.30% Premarket on February 11, 2026 After FDA Refuses to File Flu Shot mRNA-1010
On February 11, 2026, Moderna's stock fell 9.30% in premarket trading to $38.09 after the FDA issued a refuse-to-file letter for its mRNA-1010 seasonal flu vaccine. The agency criticized the Phase 3 trial design for not using the best-available standard of care for older adults, while Moderna argued the decision conflicts with prior regulatory feedback and highlighted that the vaccine met trial objectives and is under review in other major markets.
2-11